RANDOMIZED PHASE II TRIAL OF NEOADJUVANT CISPLATIN VS. DOXORUBICIN/CYCLOPHOSPHAMIDE (¿AC¿) IN WOMEN WITH NEWLY DIAGNOSED BREAST CANCER AND GERMLINE BRCA MUTATIONS
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Start Date
September 1, 2015
End Date
May 31, 2019
Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Start Date
September 1, 2015
End Date
May 31, 2019